USP7

Chr 16AD

ubiquitin specific peptidase 7

Also known as: C16DELp13.2, DEL16P13.2, HAFOUS, HAUSP, TEF1

The protein encoded by this gene belongs to the peptidase C19 family, which includes ubiquitinyl hydrolases. This protein deubiquitinates target proteins such as p53 (a tumor suppressor protein) and WASH (essential for endosomal protein recycling), and regulates their activities by counteracting the opposing ubiquitin ligase activity of proteins such as HDM2 and TRIM27, involved in the respective process. Mutations in this gene have been implicated in a neurodevelopmental disorder. [provided by RefSeq, Mar 2016]

GeneReviewsOMIMResearchGenerating clinical summary…
LOFmechanismADLOEUF 0.061 OMIM phenotype
Clinical SummaryUSP7
🧬
Gene-Disease Validity (ClinGen)
Hao-Fountain syndrome · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
56 unique Pathogenic / Likely Pathogenic· 243 VUS of 609 total submissions
📖
GeneReview available — USP7
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?
0.06LOEUF
pLI 1.000
Z-score 8.04
OE 0.01 (0.000.06)
Highly constrained

Among the most LoF-intolerant genes (~top 3%)

Missense Constraint?
5.65Z-score
OE missense 0.36 (0.320.41)
225 obs / 621.1 exp
Constrained

Extremely missense-constrained (top ~0.01%)

Observed / Expected Ratios?
LoF OE?0.01 (0.000.06)
00.351.4
Missense OE?0.36 (0.320.41)
00.61.4
Synonymous OE?1.20
01.21.6
LoF obs/exp: 1 / 77.2Missense obs/exp: 225 / 621.1Syn Z: -2.44
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongUSP7-related developmental disorderLOFAD

This gene — mechanism propensity

DN
0.2997th %ile
GOF
0.3293th %ile
LOF
0.73top 10%

The highest-scoring mechanism for this gene is loss-of-function (haploinsufficiency).

LOFprediction above median · 1 literature citation · 70% of P/LP variants are LoF · LOEUF 0.06 · ClinGen HI: Sufficient evidence for dosage pathogenicity

Literature Evidence

LOFThe consistency of clinical features among all individuals presented regardless of de novo USP7 variant type supports haploinsufficiency as a mechanism for pathogenesis and refines the clinical impact faced by affected individuals and caregivers.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 30679821

ClinVar Variant Classifications

609 submitted variants in ClinVar

Classification Summary

Pathogenic21
Likely Pathogenic35
VUS243
Likely Benign222
Benign50
Conflicting5
21
Pathogenic
35
Likely Pathogenic
243
VUS
222
Likely Benign
50
Benign
5
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
19
1
1
0
21
Likely Pathogenic
20
14
1
0
35
VUS
1
213
24
5
243
Likely Benign
0
13
122
87
222
Benign
0
4
37
9
50
Conflicting
5
Total40245185101576

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

26 pathogenic / likely-pathogenic (of 79) ClinVar copy-number / structural variants overlap USP7 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

USP7 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →